Fig. 3

Immunohistochemical (IHC) staining and mRNA expression of candidate expression in acute myeloid leukemia (AML) patient specimens. (A) Representative images of IHC staining for ATRN, CCL23, and CCL13 (×400), showing sections from patients with complete remission (CR) at the top and non-CR at the bottom. (B) The bar graph illustrates the percentage of patients showing strong staining intensity (3+) for each antibody. It compares the proportions of CR and non-CR group patients with strong staining. A t-test determined the statistical significance of differences in staining intensity between the CR and non-CR groups, indicated by * p < 0.05. (C) The Log2 (CPM) expression levels of ARTN and CCL23 from bulk RNA-seq analysis comparing CR and non-CR groups in acute myeloid leukemia patients are shown. The box plot represents the 25th and 75th percentiles, with whiskers indicating the maximum and minimum values. Solid lines within the boxes mark the medians. Statistical significance is denoted by * p < 0.05 and ** p < 0.01. (D) The Human Protein Atlas data show that ARTN and CCL23 are expressed at significantly higher levels (p < 0.001) in AML patients compared to those with other cancers